# Vaccine Therapy in Treating Patients With Myelodysplastic Syndromes

> **NCT00361296** · EARLY_PHASE1 · TERMINATED · sponsor: **Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins** · enrollment: 9 (actual)

## Conditions studied

- Myelodysplastic Syndromes

## Interventions

- **BIOLOGICAL:** K562/GM-CSF cell vaccine

## Key facts

- **NCT ID:** NCT00361296
- **Lead sponsor:** Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
- **Sponsor class:** OTHER
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2007-09
- **Primary completion:** 2009-10
- **Final completion:** 2010-01
- **Target enrollment:** 9 (ACTUAL)
- **Why stopped:** Loss of funding
- **Last updated:** 2023-03-23

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00361296

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00361296, "Vaccine Therapy in Treating Patients With Myelodysplastic Syndromes". Retrieved via AI Analytics 2026-06-12 from https://api.ai-analytics.org/clinical/NCT00361296. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*